Answers are grounded in this paper and cite their sources.
Demonstrates that atorvastatin decreases invasion of osteosarcoma cells by inhibiting the RhoA-JNK-c-Jun-MMP2 cascade, suggesting a therapeutic pathway to prevent metastasis.
Osteosarcoma is characterized by a high malignant and metastatic potential, which points to the need for new therapeutic strategies to prevent cell metastasis. In this study, we show that statin-induced HMG-CoA reductase inhibition reduces cell migration and invasion in human and murine osteosarcoma cells, independently of the genotype. The statin-induced reduction of cell migration and invasion was independent of induction of apoptosis and was geranylgeranylpyrophosphate-dependent. The statin reduced matrix metalloproteinase (MMP) 2, 9, and 14 and TIMP2 expression or activity in invading cells. Forced expression of MMP2 and MMP14 overcame the inhibitory effect of the statin on cell invasion, suggesting a role for these MMPs in invasive potential. We also investigated the mechanisms involved in the reduced MMP2 activity and cell invasion. Inhibition of JNK, but not ERK1/2 signaling, reduced MMP2 activity. Pharmacological or constitutive activation of JNK overcame the reduced MMP2 activity and cell invasion induced by the statin. The statin decreased JNK phosphorylation and c-Jun nuclear translocation, suggesting that HMG-CoA reductase inhibition targets the JNK-c-Jun signaling pathway. We showed that mevalonate or geranylgeranylpyrophosphate treatment prevented the statin-induced reduction in JNK phosphorylation, MMP2 activity, and cell invasion. Forced expression of a constitutively active form of RhoA increased JNK phosphorylation and overcame the inhibitory effect of atorvastatin on MMP2 activity and cell invasion. The data establish a link between RhoA, JNK, c-Jun, and MMP2 activity that is functionally involved in the reduction in osteosarcoma cell invasion by the statin. This suggests a novel strategy targeting RhoA-JNK-c-Jun signaling to reduce osteosarcoma cell tumorigenesis. Osteosarcoma is characterized by a high malignant and metastatic potential, which points to the need for new therapeutic strategies to prevent cell metastasis. In this study, we show that statin-induced HMG-CoA reductase inhibition reduces cell migration and invasion in human and murine osteosarcoma cells, independently of the genotype. The statin-induced reduction of cell migration and invasion was independent of induction of apoptosis and was geranylgeranylpyrophosphate-dependent. The statin reduced matrix metalloproteinase (MMP) 2, 9, and 14 and TIMP2 expression or activity in invading cells. Forced expression of MMP2 and MMP14 overcame the inhibitory effect of the statin on cell invasion, suggesting a role for these MMPs in invasive potential. We also investigated the mechanisms involved in the reduced MMP2 activity and cell invasion. Inhibition of JNK, but not ERK1/2 signaling, reduced MMP2 activity. Pharmacological or constitutive activation of JNK overcame the reduced MMP2 activity and cell invasion induced by the statin. The statin decreased JNK phosphorylation and c-Jun nuclear translocation, suggesting that HMG-CoA reductase inhibition targets the JNK-c-Jun signaling pathway. We showed that mevalonate or geranylgeranylpyrophosphate treatment prevented the statin-induced reduction in JNK phosphorylation, MMP2 activity, and cell invasion. Forced expression of a constitutively active form of RhoA increased JNK phosphorylation and overcame the inhibitory effect of atorvastatin on MMP2 activity and cell invasion. The data establish a link between RhoA, JNK, c-Jun, and MMP2 activity that is functionally involved in the reduction in osteosarcoma cell invasion by the statin. This suggests a novel strategy targeting RhoA-JNK-c-Jun signaling to reduce osteosarcoma cell tumorigenesis. Osteosarcoma is the most common primary tumor of bone in children and young adults (1Himelstein B.P. Curr. Opin. Oncol. 1998; 10: 326-333Crossref PubMed Scopus (20) Google Scholar). These tumors are characterized by a highly malignant and metastatic potential (2Bruland O.S. Hoifodt H. Saeter G. Smeland S. Fodstad O. Clin. Cancer Res. 2005; 11: 4666-4673Crossref PubMed Scopus (84) Google Scholar). The metastasis process is a complex process that is dependent on cancer cell capacity to invade, migrate, and proliferate (3Woodhouse E.C. Chuaqui R.F. Liotta L.A. Cancer. 1997; 80: 1529-1537Crossref PubMed Google Scholar, 4Van Noorden C.J. Acta Histochem. 1998; 100: 344-354Crossref PubMed Scopus (6) Google Scholar). Consistently, cell invasion and migration are highly related to the activity of matrix metalloproteinases (MMPs) 2The abbreviations used are: MMP, matrix metalloproteinase; FPP, farnesylpyrophosphate; GGPP, geranylgeranylpyrophosphate; HMG-CoA, 3-hydroxy 3-methylglutaryl coenzyme A; JNK, c-Jun N-terminal kinase; ERK, extracellular signal-regulated kinase; DMEM, Dulbecco's modified Eagle's medium; HUVEC, human umbilical vein endothelial cell(s); z, benzyloxycarbonyl; fmk, fluoromethyl ketone; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; TIMP, tissue inhibitor of metalloproteinases; MEK, mitogen-activated protein kinase/ERK kinase. 2The abbreviations used are: MMP, matrix metalloproteinase; FPP, farnesylpyrophosphate; GGPP, geranylgeranylpyrophosphate; HMG-CoA, 3-hydroxy 3-methylglutaryl coenzyme A; JNK, c-Jun N-terminal kinase; ERK, extracellular signal-regulated kinase; DMEM, Dulbecco's modified Eagle's medium; HUVEC, human umbilical vein endothelial cell(s); z, benzyloxycarbonyl; fmk, fluoromethyl ketone; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; TIMP, tissue inhibitor of metalloproteinases; MEK, mitogen-activated protein kinase/ERK kinase. that regulate many processes involved in tumor evolution, such as cell growth, migration, and extracellular matrix degradation (5Sternlicht M.D. Werb Z. Annu. Rev. Cell Dev. Biol. 2001; 17: 463-516Crossref PubMed Scopus (3170) Google Scholar). Notably, MMP2 (gelatinase A) and MMP9 (gelatinase B) have been implicated in invasion and metastatic processes in several cancers (6Coussens L.M. Fingleton B. Matrisian L.M. Science. 2002; 295: 2387-2392Crossref PubMed Scopus (2331) Google Scholar, 7Egeblad M. Werb Z. Nat. Rev. Cancer. 2002; 2: 161-174Crossref PubMed Scopus (5030) Google Scholar). The cholesterol-lowering agents statins act as inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which catalyzes the conversion of HMG-CoA into mevalonate. Mevalonate is converted into farnesylpyrophosphate (FPP) or geranylgeranylpyrophosphate (GGPP) that can be anchored onto intracellular proteins through prenylation, thereby ensuring relocalization of target proteins to cell membranes (8Stenner-Liewen F. Reed J.C. Cancer Res. 2003; 63: 263-268Google Scholar, 9Waxman D.J. Schwartz P.S. Cancer Res. 2003; 63: 8563-8572PubMed Google Scholar). Inhibition of HMG-CoA reductase results in alteration of prenylation of small G proteins such as RhoA (10Aznar S. Lacal J.C. Cancer Lett. 2001; 165: 1-10Crossref PubMed Scopus (287) Google Scholar), which regulates cell cycle and survival by modulating downstream signaling pathways (11Wong W.W. Dimitroulakos J. Minden M.D. Penn L.Z. Leukemia. 2002; 16: 508-519Crossref PubMed Scopus (473) Google Scholar, 12Graaf M.R. Richel D.J. van Noorden C.J. Guchelaar H.J. Cancer Treat Rev. 2004; 30: 609-641Abstract Full Text Full Text PDF PubMed Scopus (260) Google Scholar). Accordingly, inhibition of HMG-CoA reductase by statins was found to trigger apoptosis in several cancer cells (10Aznar S. Lacal J.C. Cancer Lett. 2001; 165: 1-10Crossref PubMed Scopus (287) Google Scholar, 11Wong W.W. Dimitroulakos J. Minden M.D. Penn L.Z. Leukemia. 2002; 16: 508-519Crossref PubMed Scopus (473) Google Scholar, 12Graaf M.R. Richel D.J. van Noorden C.J. Guchelaar H.J. Cancer Treat Rev. 2004; 30: 609-641Abstract Full Text Full Text PDF PubMed Scopus (260) Google Scholar, 13Li Y.C. Park M.J. Ye S.K. Kim C.W. Kim Y.N. Am. J. Pathol. 2006; 168 (and 1404–1405): 1107-1118Abstract Full Text Full Text PDF PubMed Scopus (378) Google Scholar). We recently showed that lipophilic statins dose-dependently induce apoptosis in human osteosarcoma cells through inhibition of RhoA prenylation and reduced ERK1/2-Bcl2 survival pathway (14Fromigue O. Hay E. Modrowski D. Bouvet S. Jacquel A. Auberger P. Marie P.J. Cell Death Differ. 2006; 13: 1845-1856Crossref PubMed Scopus (93) Google Scholar). In addition to affect cell survival, inactivation of RhoA may also inhibit human cancer cell migration and invasion (15Denoyelle C. Vasse M. Korner M. Mishal Z. Ganne F. Vannier J.P. Soria J. Soria C. Carcinogenesis. 2001; 22: 1139-1148Crossref PubMed Scopus (279) Google Scholar, 16Sawada K. Morishige K. Tahara M. Kawagishi R. Ikebuchi Y. Tasaka K. Murata Y. Cancer Res. 2002; 62: 6015-6020PubMed Google Scholar, 17Kusama T. Mukai M. Tatsuta M. Nakamura H. Inoue M. Int. J. Oncol. 2006; 29: 217-223PubMed Google Scholar). One possible mechanism is that inactivation of RhoA may down-regulate the expression of MMP2 or MMP9 (18Denoyelle C. Albanese P. Uzan G. Hong L. Vannier J.P. Soria J. Soria C. Cell Signal. 2003; 15: 327-338Crossref PubMed Scopus (106) Google Scholar, 19Thunyakitpisal P.D. Chaisuparat R. J. Pharmacol. Sci. 2004; 94: 403-409Crossref PubMed Scopus (43) Google Scholar). However, the mechanisms by which RhoA inactivation may control MMPs and cell migration and invasion are not fully understood. In this study, we show that statin-induced inhibition of HMG-CoA reductase decreases cell migration and invasion in human and murine osteosarcoma cells through a mechanism involving inhibition of RhoA-JNK-c-Jun signaling and MMP2 activity. Our results thus implicate a role for JNK signaling in statin-induced inhibition of human cancer cell migration and invasion. Cell Cultures—We used human p53-deficient SaOS2 osteosarcoma cells (ATCC, Manassas, VA) (20Rodan S.B. Imai Y. Thiede M.A. Wesolowski G. Thompson D. Bar-Shavit Z. Shull S. Mann K. Rodan G.A. Cancer Res. 1987; 47: 4961-4966PubMed Google Scholar), p53 mutant and ARF-deficient MG63 cells, ARF mutant U2OS cells, and aggressive CAL72 cells (21Rochet N. Dubousset J. Mazeau C. Zanghellini E. Farges M.F. de Novion H.S. Chompret A. Delpech B. Cattan N. Frenay M. Gioanni J. Int. J. Cancer. 1999; 82: 282-285Crossref PubMed Scopus (40) Google Scholar). Murine K7M2 (ATCC) derived from mouse osteosarcoma are highly tumorigenic in vivo (22Khanna C. Prehn J. Yeung C. Caylor J. Tsokos M. Helman L. Clin. Exp. Metastasis. 2000; 18: 261-271Crossref PubMed Scopus (158) Google Scholar). Normal fetal human osteoblastic cells (FHSO6) were derived from the bone marrow stroma (23Fromigue O. Kheddoumi N. Lomri A. Marie P.J. Body J.J. J. Bone Miner. Res. 2001; 16: 1600-1610Crossref PubMed Scopus (31) Google Scholar). The cells were routinely cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen) supplemented with 10% heat-inactivated fetal calf serum, 1% l-glutamine, and penicillin/streptomycin (10,000 units/ml and 10,000 μg/ml, respectively) in in The were or umbilical vein endothelial cells by were by The umbilical was in and the umbilical vein was with and for with were by the vein with onto and cultured in endothelial cell medium supplemented with in a and was by J. GGPP, FPP, and were from was from RhoA, and were from and were from TIMP2 was from MMP2 and MMP9 were from Cell was from was from The active was from The and were from of The was from Cell and migration was in the modified cell de as with A. O. C. N. P. Marie P.J. Modrowski D. Cancer Res. PubMed Scopus Google Scholar). the cells were with or statin in and for The cells that not through the were from the of the The cells to the were in in and with The membranes were from the and were and for in in cell invasion were with a migration was in which were and cultured to were and for in in the migration of HUVEC, which were from osteosarcoma cells. Cell was as (14Fromigue O. Hay E. Modrowski D. Bouvet S. Jacquel A. Auberger P. Marie P.J. Cell Death Differ. 2006; 13: 1845-1856Crossref PubMed Scopus (93) Google Scholar). cell was by the by T. J. PubMed Scopus Google was to the medium for the of The were and the cells were in were a We used for and the were cells were in on for The were for 10,000 to protein was by a protein and on MMP2 activity was by a in to the and for protein 14 cell were the and to the activity was by The were and protein were on 10% in the of The were in for and in for The were with in and in Cell were to the the cells were cultured for in supplemented with 10% fetal calf and with and of of and of the was The cells were for and of supplemented with fetal calf was to the the medium was with cells were in for on addition of of The were for to in The were in for on a and to and was by to the of from were murine and for The were by and The were to as The were as and for and for and for and for and and for S. cell were as (14Fromigue O. Hay E. Modrowski D. Bouvet S. Jacquel A. Auberger P. Marie P.J. Cell Death Differ. 2006; 13: 1845-1856Crossref PubMed Scopus (93) Google Scholar). the proteins were on and onto membranes The were for in and on a with primary in The membranes were with and for with in the were with and was between the were the of with a of Osteosarcoma Cell of the potential of osteosarcoma cell with to osteoblastic cells derived from fetal human bone marrow (23Fromigue O. Kheddoumi N. Lomri A. Marie P.J. Body J.J. J. Bone Miner. Res. 2001; 16: 1600-1610Crossref PubMed Scopus (31) Google Scholar). In cell migration was modified of the cells were to with potential SaOS2 cells showed the capacity to migrate, MG63 cells showed the The cell potential. this we the of atorvastatin on SaOS2 cell migration potential. We found that atorvastatin reduced cell migration in a We the effect of atorvastatin the of on cell We found that the statin reduced cell migration in human or murine osteosarcoma cell but not cell migration potential results were with not We showed that atorvastatin reduces osteosarcoma cell by induction of apoptosis (14Fromigue O. Hay E. Modrowski D. Bouvet S. Jacquel A. Auberger P. Marie P.J. Cell Death Differ. 2006; 13: 1845-1856Crossref PubMed Scopus (93) Google Scholar). We thus the reduction in cell migration by the statin was related to apoptosis induction with a inhibitor The addition of fully prevented the reduction in cell induced by the statin but not prevent the statin-induced inhibition of cell migration These results that atorvastatin reduces the in cell migration potential of human and murine osteosarcoma cells, independently of the or of Osteosarcoma Cell of the effect of atorvastatin on in cell invasion. this we used to the extracellular matrix or to the endothelial for in cell migration, the osteosarcoma cell invasion potential in U2OS cells were the most invasive cells with cells In MG63 cells showed invasive potential through through 2, with atorvastatin reduced cell invasion in invading osteosarcoma cell to but effect on invasive potential of human osteoblastic cells The addition of not prevent the effect of atorvastatin on cell invasion that the inhibitory effect of atorvastatin was independent of effect on cell but reduced cell invasion of invading osteosarcoma cells as for migration and invasion effect was in osteoblastic cells. These data show that atorvastatin reduces the of osteosarcoma cell invading extracellular matrix by or endothelial by osteoblastic cells were not to atorvastatin in of in cell invasion potential. the and of MMPs investigated the role of MMP2 and which are to role in the invasive process J.P. Cancer Rev. 2006; PubMed Scopus Google Scholar). MMP2 is to be in TIMP2 and G. G.A. J. Biol. Full Text Full Text PDF PubMed Scopus Google Scholar, E. F. E. C. A. A. G. J. Biol. 2000; Full Text Full Text PDF PubMed Scopus Google Scholar). we investigated the expression of these in osteosarcoma cells atorvastatin We found that atorvastatin reduced and TIMP2 in U2OS cells results were found in invading osteosarcoma cell and K7M2 data not atorvastatin reduced activity, by and reduced MMP14 activity, by also reduced and TIMP2 protein in U2OS and in invading osteosarcoma cell and K7M2 data not as by The reduction in MMP2 activity by the statin was in U2OS cells, MG63 cells, which are cells, and cells, which are osteoblastic cells and invading cells, were not the role of MMP2 in cell invasion, U2OS cells were with expression MMP2 or Forced expression of MMP2 MMP14 the inhibition of cell invasion induced by atorvastatin in these cells These data that atorvastatin reduces expression and activity, in reduction in the invasive capacity in murine and human osteosarcoma cells. in the Inhibition of Osteosarcoma Cell by showed that atorvastatin prenylation and activity of process (14Fromigue O. Hay E. Modrowski D. Bouvet S. Jacquel A. Auberger P. Marie P.J. Cell Death Differ. 2006; 13: 1845-1856Crossref PubMed Scopus (93) Google Scholar). We thus the effect of geranylgeranylpyrophosphate (GGPP) on the statin-induced inhibition of U2OS cell invasion. We found that the addition of prevented the inhibition of in cell invasion induced by the statin fully the of activity in the inhibition of cell by we U2OS cells with a a constitutively active form of RhoA This the reduction in RhoA by independently of the prenylation or Forced expression of also the reduction in U2OS cell invasion induced by atorvastatin These results that atorvastatin osteosarcoma cell invasion through inhibition of prenylation and activity. The in MMP2 by on to the mechanisms the reduction of MMP2 activity by atorvastatin in osteosarcoma cells. We the role of in the inhibitory effect of atorvastatin on MMP2 activity or mevalonate (14Fromigue O. Hay E. Modrowski D. Bouvet S. Jacquel A. Auberger P. Marie P.J. Cell Death Differ. 2006; 13: 1845-1856Crossref PubMed Scopus (93) Google Scholar). We found that mevalonate or the MMP2 activity in U2OS cells, effect expression of prevented the inhibition of MMP2 activity induced by the statin the link between and MMP2 activity. These data that and inhibition of activity by atorvastatin the reduced MMP2 activity in osteosarcoma cells. The in MMP2 by JNK investigated the signaling pathway involved in the reduction of MMP2 activity induced by the statin in osteosarcoma cells. We showed that reduced is for the effect of atorvastatin in osteosarcoma cells (14Fromigue O. Hay E. Modrowski D. Bouvet S. Jacquel A. Auberger P. Marie P.J. Cell Death Differ. 2006; 13: 1845-1856Crossref PubMed Scopus (93) Google Scholar). In this study, we used a and inhibitor of JNK, which reduced and protein in MMP2 activity was reduced by the JNK inhibitor but not by the inhibitor in U2OS cells in activation of JNK for the prevented the reduction in MMP2 activity by atorvastatin in U2OS cells were found in the osteosarcoma cell not These data a role for JNK signaling in statin-induced reduction in MMP2 activity. Consistently, of a and JNK, which JNK phosphorylation prevented the reduction in MMP2 activity induced by atorvastatin that JNK is a downstream target of HMG-CoA reductase inhibition in osteosarcoma cells, we investigated the in of c-Jun from the to the in atorvastatin reduced c-Jun nuclear the activity through complex was dose-dependently reduced in U2OS cells in the of atorvastatin these data that the statin reduces MMP2 activity through inhibition of JNK phosphorylation and establish JNK-c-Jun as a downstream target of HMG-CoA reductase inhibition in osteosarcoma cells. Inhibition of MMP2 and Cell by from of to the link between and JNK signaling, we used mevalonate or downstream and to the effect of atorvastatin on We found that with or mevalonate protein in U2OS cells, effect This that JNK activation is dependent on in osteosarcoma cells. This is by the that with the increased the the link between and JNK, U2OS cells were with the and JNK, which increased the Forced expression of fully prevented the reduced invasion induced by atorvastatin These data that HMG-CoA reductase inhibition by the statin decreases the of invading cells through a mechanism involving inactivation of the RhoA-JNK-c-Jun signaling pathway. results a in which HMG-CoA reductase inhibition by the statin reduces activity through inhibition of to reduction in JNK phosphorylation and c-Jun nuclear translocation, which results in reduced MMPs and protein expression and inhibition of MMP2 activity, which a role for JNK signaling in statin-induced reduction in MMP2 activity and invasion process In this study, we show that statin-induced HMG-CoA reductase inhibition reduces cell migration and invasion in osteosarcoma cells, and we a mechanism involving activity in these These data to a potential effect by inhibition of HMG-CoA reductase and activity in osteosarcoma cells. We show that atorvastatin reduces in cell migration and invasion in a of osteosarcoma cell of human and murine suggesting that this inhibitory effect is independent of the cell genotype. The inhibitory effect of atorvastatin on cell migration was not to decreased cell activity not inhibition of cell migration induced by the statin. This suggests a effect of the statin on tumor cell invasion. We that the reduced osteosarcoma cell invasion induced by the statin may from reduced matrix metalloproteinases (MMPs) activity. expression of MMPs is to role in tumor cell invasion and in several cancers (2Bruland O.S. Hoifodt H. Saeter G. Smeland S. Fodstad O. Clin. Cancer Res. 2005; 11: 4666-4673Crossref PubMed Scopus (84) Google Scholar, L.M. Fingleton B. Matrisian L.M. Science. 2002; 295: 2387-2392Crossref PubMed Scopus (2331) Google Scholar, 7Egeblad M. Werb Z. Nat. Rev. Cancer. 2002; 2: 161-174Crossref PubMed Scopus (5030) Google Scholar, F. Reed J.C. Cancer Res. 2003; 63: 263-268Google osteosarcoma K. K. S. Fodstad O. J. Res. 2005; Full Text Full Text PDF PubMed Scopus Google Scholar). MMP2 and MMP9 are cell MMPs that are highly and in invasive human osteosarcoma cells, suggesting that MMPs are for cancer cell invasion K. K. S. Fodstad O. J. Res. 2005; Full Text Full Text PDF PubMed Scopus Google Scholar). Notably, MMP9 are functionally related to the invasion of cancer cells J. A. van Cell Biol. 2005; PubMed Scopus (260) Google Scholar), and MMP9 expression can be by statins in cells 2000; PubMed Scopus Google Scholar, D.J. Res. 2004; PubMed Scopus Google Scholar, D.J. J. 2005; PubMed Scopus Google Scholar, P. S. L. D.J. J. Cell Full Text Full Text PDF PubMed Scopus Google and osteosarcoma cells P.D. Chaisuparat R. J. Pharmacol. Sci. 2004; 94: 403-409Crossref PubMed Scopus (43) Google Scholar). In the study, we show that atorvastatin dose-dependently reduced MMP2 activity in invading osteosarcoma cells. the statin not MMP2 activity in or osteoblastic cells, suggesting that the statin may target MMPs in invading osteosarcoma cells. A pathway that to the activation of the is activation by a complex TIMP2 and G. G.A. J. Biol. Full Text Full Text PDF PubMed Scopus Google Scholar). we found that atorvastatin reduced the expression of MMP14 as as that the statin reduced the expression of of the MMP2 Our that expression of MMP2 MMP14 overcame the inhibitory effect of atorvastatin on cell invasion that these MMPs are involved in osteosarcoma invasive potential. This also that the reduced osteosarcoma cell invasion induced by the statin results in from the inhibition of MMP2 expression and The inhibitory effect of statin on MMP2 activity may be to the metastatic potential the MMP2 activation with osteosarcoma cell invasion Y. K. K. F. S. Y. J. Cancer Res. 2001; PubMed Scopus Google Scholar). that osteosarcoma cell migration and invasion can be reduced by the we investigated the signaling mechanisms involved in the reduced MMP2 activity and cell invasion. protein are signaling pathways MMPs H.S. 2006; 11: PubMed Scopus Google Scholar). However, ERK1/2 and JNK were found to the of MMP2 in osteosarcoma cells E. Am. J. 2006; PubMed Scopus Google Scholar, Y.C. Carcinogenesis. PubMed Scopus Google Scholar). In study, we found that JNK, but not ERK1/2 reduced MMP2 activity, which points to a role for JNK in the of MMP2 activity in osteosarcoma cells. This is by that JNK activation by or by treatment with overcame MMP2 activity and prevented the in cell invasion induced by the statin. This for the a link between HMG-CoA reductase, JNK, and MMP2 activity and suggests the of JNK in the osteosarcoma invasion The c-Jun is of several processes A. K. M. Sci. S. A. 2001; PubMed Scopus Google Scholar, R. Nat. Rev. Cancer. 2003; PubMed Scopus Google Scholar, K. K. A. M. 2004; 15: Full Text Full Text PDF PubMed Scopus Google Scholar). of c-Jun by JNK results in of the complex to the and activation of that the MMP2 J. Y. Cell Biol. 1997; 17: PubMed Scopus Google Scholar). Our that statin reduced c-Jun to the suggests that HMG-CoA reductase inhibition targets the JNK-c-Jun signaling pathway to MMP2 activity and osteosarcoma cell invasion. These data a link between JNK, and osteosarcoma cell invasion and JNK as a novel potential target for We to the statin may to the inhibition of in osteosarcoma cells. Inhibition of HMG-CoA reductase is to to in mevalonate and downstream such as or We found that mevalonate or the statin-induced reduction in MMP2 activity and osteosarcoma cell invasion, a role for in the downstream This is by that mevalonate or in osteosarcoma cells. These data to a role of in the of the invasion One possible downstream target is the RhoA, a that Our that of a constitutively active form of RhoA increased and overcame the inhibitory effect of atorvastatin on MMP2 activity and cell invasion that a role in the effect of statin in osteosarcoma cells. data a mechanism by which inhibition of HMG-CoA reductase by the statin and decreased prenylation results in reduced JNK-c-Jun signaling, decreased MMP2 activity, and cell invasion in osteosarcoma cells These in may be to in vivo increased expression of MMP2 with in human osteosarcoma M. Y. T. Y. K. N. Int. J. Oncol. 2006; Google Scholar), and tumor cells show HMG-CoA reductase activity G. B. Int. J. Cancer. 1999; PubMed Scopus Google and increased JNK signaling (11Wong W.W. Dimitroulakos J. Minden M.D. Penn L.Z. Leukemia. 2002; 16: 508-519Crossref PubMed Scopus (473) Google Scholar, 13Li Y.C. Park M.J. Ye S.K. Kim C.W. Kim Y.N. Am. J. Pathol. 2006; 168 (and 1404–1405): 1107-1118Abstract Full Text Full Text PDF PubMed Scopus (378) Google Scholar, A. A. G. 1998; PubMed Scopus Google Scholar, D.J. A. 2003; PubMed Scopus Google Scholar, A. J. Biol. 2004; Full Text Full Text PDF PubMed Scopus Google Scholar). Notably, aggressive osteosarcoma tumors show increased expression A. A. G. 1998; PubMed Scopus Google Scholar, D.J. A. 2003; PubMed Scopus Google Scholar, J.P. D. L. M. O. M. J. Clin. 2005; PubMed Scopus Google Scholar, R. Rev. 2005; PubMed Scopus Google Scholar), which may to tumor and invasion. data that JNK and MMP2 expression and with cancer cell migration and invasion Cancer Res. 2006; PubMed Scopus Google Scholar, B. M.J. P. Y. Cancer Res. 2006; PubMed Scopus Google Scholar). The that HMG-CoA reductase inhibition reduces cell invasion and migration in osteosarcoma cells by signaling and MMP2 activity suggests a novel strategy to target RhoA-JNK-c-Jun to reduce osteosarcoma cell and tumorigenesis. We J. for N. for the of CAL72 cells, and O. for the of HUVEC, A. de for the MMP2 and MMP14 expression R. J. for the expression and P. for the RhoA mutant
No takes yet. Share an insight, caveat, or question.
Fromigué et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: